Molecular Involvement and Prognostic Importance of Fms-like Tyrosine Kinase 3 in Acute Myeloid Leukemia

被引：3
作者：
Shahab, Sadaf [1 ]
Shamsi, Tahir S. [1 ]
Ahmed, Nuzhat [1 ]
机构：
[1] Natl Inst Blood Dis & Bone Marrow Transplantat, Karachi, Pakistan
来源：
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2012年 / 13卷 / 09期
关键词：
AML; FLT3; ITDs; (TKD); leukemia-specific recognition markers; prognostic marker; INTERNAL TANDEM DUPLICATION; FLT3; GENE; MYELODYSPLASTIC SYNDROME; MYELOGENOUS LEUKEMIA; NORMAL CYTOGENETICS; MUTATIONS; ASSOCIATION; IDENTIFICATION; ACTIVATION; EXPRESSION;
D O I：
10.7314/APJCP.2012.13.8.4215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML (Acute myeloid leukemia) is a form of blood cancer where growth of myeloid cells occurs in the bone marrow. The prognosis is poor in general for many reasons. One is the presence of leukaemia-specific recognition markers such as FLT3 (fms-like tyrosine kinase 3). Another name of FLT3 is stem cell tyrosine kinase-1 (STK1), which is known to take part in proliferation, differentiation and apoptosis of hematopoietic cells, usually being present on haemopoietic progenitor cells in the bone marrow. FLT3 act as an independent prognostic factor for AML. Although a vast literature is available about the association of FLT3 with AML there still is a need of a brief up to date overview which draw a clear picture about this association and their effect on overall survival.
引用
收藏
页码：4215 / 4220
页数：6
相关论文
共 50 条
  • [31] A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia
    Sellmer, Andreas
    Pilsl, Bernadette
    Beyer, Mandy
    Pongratz, Herwig
    Wirth, Lukas
    Elz, Sigurd
    Dove, Stefan
    Henninger, Sven Julian
    Spiekermann, Karsten
    Polzer, Harald
    Klaeger, Susan
    Kuster, Bernhard
    Boehmer, Frank D.
    Fiebig, Heinz-Herbert
    Kraemer, Oliver H.
    Mahboobi, Siavosh
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 193
  • [32] Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia
    Gill, Harinder
    Man, Cheuk-Him
    Ip, Alvin H. W.
    Choi, William W. L.
    Chow, Howard C. H.
    Kwong, Yok-Lam
    Leung, Anskar Y. H.
    [J]. HAEMATOLOGICA, 2015, 100 (07) : E250 - E253
  • [33] Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia
    Kim, Miryoung
    Williams, Sherry
    [J]. ANNALS OF PHARMACOTHERAPY, 2018, 52 (04) : 364 - 369
  • [34] Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment
    Ma, Chenchen
    Cui, Siyuan
    Xu, Ruirong
    [J]. CURRENT MEDICINAL CHEMISTRY, 2024, 31 (29) : 4657 - 4686
  • [35] FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies
    Egbuna, Chukwuebuka
    Patrick-Iwuanyanwu, Kingsley C.
    Onyeike, Eugene N.
    Khan, Johra
    Alshehri, Bader
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (22) : 12248 - 12259
  • [36] The incidence and prognostic effect of Fms-like tyrosine kinase 3 gene internal tandem and nucleolar phosphoprotein 1 genes in acute myeloid leukaemia A PRISMA-compliant systematic review and meta-analysis
    Liu, Heping
    Zhang, Xiaolian
    Li, Ming
    Zhou, Wei
    Jiang, Guangrong
    Yin, Weihua
    Song, Chunping
    [J]. MEDICINE, 2020, 99 (51) : E23707
  • [37] Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
    Koo, Bon-Kwan
    Choi, Eun-Ji
    Moon, Ju Hyun
    Kim, Ji Yun
    Park, Hyunkyung
    Park, Han-Seung
    Choi, Yunsuk
    Lee, Jung-Hee
    Lee, Kyoo-Hyung
    Choi, Eun Kyung
    Kim, Eunji
    Lee, Je-Hwan
    Hur, Eun-Hye
    [J]. BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [38] Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
    Cortes, Jorge E.
    Kantarjian, Hagop
    Foran, James M.
    Ghirdaladze, Darejan
    Zodelava, Mamia
    Borthakur, Gautam
    Gammon, Guy
    Trone, Denise
    Armstrong, Robert C.
    James, Joyce
    Levis, Mark
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3681 - +
  • [39] Nucleophosmin (NPM1-A) and FMS-like tyrosine kinase 3 (FLT3/ITD) mutations in acute myeloid leukaemia with a normal karyotype: frequency and prognostic significance
    Akl, Hosneia K. H.
    Gawish, Heba H.
    Abou Taleb, Fouad M.
    [J]. EGYPTIAN JOURNAL OF HAEMATOLOGY, 2012, 37 (04) : 200 - 206
  • [40] Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications-Positive Acute Myeloid Leukemia Cells
    Song, Guiyun
    Valdez, Benigno C.
    Li, Yang
    Liu, Yan
    Champlin, Richard E.
    Andersson, Borje S.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (11) : 1687 - 1695
12345